The US Drug Enforcement Administration (DEA) has publicly announced in the Federal Register that it is increasing its marijuana production quota from 21 kilograms to 650 kilograms (about 1,443 pounds) in order to meet increasing demand for the plant from clinical investigators.
Lawmakers in some half-dozen states are poised to enact cannabidiol-specific legislation. But will these measures ultimately help patients?
While some media outlets are reporting that the passage of these measures are akin to ‘approving medical marijuana,’ such claims are far from accurate.
Lawmakers in four states — Alabama, Georgia, Kentucky, and Utah — are poised to enact legislation in the coming days/weeks aimed at providing patients, primarily children with forms of intractable epilepsy, with strains of cannabis and/or cannabis extracts high in the compound cannabidiol (CBD). But a closer look at the text of these proposed laws indicates that, in fact, they are largely unworkable and will most likely provide no tangible relief or protection for the patient community they are intended to serve.
In recent weeks, lawmakers in several states have moved forward with legislative proposals to permit specific strains and/or extracts of cannabis possessing high quantities of the cannabinoid cannabidiol (CBD), but otherwise maintaining criminal prohibitions on the whole plant. Is this new direction in the best interest of patients?
2013 will go down on record as one of the most significant years in the history of marijuana law reform. Here’s why.
Cananbidiol (CBD), a non-psychotropic cannabinoid, alleviates psychotic symptoms and may hold promise as an alternative antipsychotic treatment, according to a review published in the November issue of the journal Neuropsychopharmacology.
Republican Gov. Chris Christie has signed legislation, Senate Bill 2842, into law modifying aspects of the state’s medical marijuana regulations.